Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3

Status

Terminated 3Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 6Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Carcinoma, Hepatocellular 46Colorectal Neoplasms 33Stomach Neoplasms 31Esophageal Squamous Cell Carcinoma 27Squamous Cell Carcinoma of Head and Neck 20Esophageal Neoplasms 14Small Cell Lung Carcinoma 13Neoplasm Metastasis 13Lung Neoplasms 13Rectal Neoplasms 12Head and Neck Neoplasms 12Advanced Solid Tumor 12Triple Negative Breast Neoplasms 11Cholangiocarcinoma 11Nasopharyngeal Carcinoma 10Melanoma 10Uterine Cervical Neoplasms 9Recurrence 9Neoplasms 9Colonic Neoplasms 9Pancreatic Neoplasms 7Urinary Bladder Neoplasms 6Solid Tumor 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Sarcoma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Carboplatin 4spartalizumab 3sintilimab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Solid Tumor × tislelizumab × Clear all
NCT06487858 2026-05-11

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

BeOne Medicines

Phase 1 Terminated
42 enrolled
Other solid neoplasm

Solid Tumor

NCT06349837 2026-05-01

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Sichuan University

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Withdrawn
Other solid neoplasm

Solid Tumor

NCT05494762 2025-05-01

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Terminated
55 enrolled
Other solid neoplasm

Solid Tumor

NCT05581719 2024-04-17

A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy

Enlivex Therapeutics RDO Ltd.

Phase 1/2 Terminated
14 enrolled
Other solid neoplasm

Solid Tumor

NCT05833984 2023-04-27

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 1/2 Unknown
309 enrolled
LymphoidOther solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡